Back to homepage

Respiratory

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases

Authors: Valeria Nucera MD, Elisabetta Gerratana MD, Manuela Giallanza MD, Laura La Corte MD, Donatella Sangari MD, Fabiola Atzeni MD, PhD

This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related interstitial lung disease, particularly in the case of patients with progressive Interstitial lung diseases.

More

Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review

Authors: Giulia Cassone MD, PhD, Marco Sebastiani MD, Caterina Vacchi MD, PhD, Gian Luca Erre MD, Carlo Salvarani MD, Andreina Manfredi MD, PhD

This review describes the available data and recent advances on the effectiveness and safety of MMF for the treatment of ILD related to RD, including rheumatoid arthritis, systemic sclerosis, primary Sjögren syndrome, systemic lupus erythematosus, idiopathic inflammatory myopathies, undifferentiated connective tissue disease, interstitial pneumonia with autoimmune features and antineutrophil cytoplasmic antibody-associated vasculitis.

More

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Authors: Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

More

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Authors: Gian Luca Erre MD, PhD, Marco Sebastiani PhD, Andreina Manfredi MD, Elisabetta Gerratana MD, Fabiola Atzeni MD, Giuseppe Passiu MD, Arduino A Mangoni MD

This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.

More

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Authors: Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

In this review, the available information on the antithrombotic management of atrial fibrillation patients at discharge after COVID-19 infection is updated. In addition, a practical algorithm, considering renal and liver function, which facilitates the anticoagulation choice at discharge is presented.

More